Search
Rigel Pharmaceuticals Inc
RIGLAdd to Watchlist
36.815USD
-1.245-3.27%
Close 07-31 16:00（ET）Quotes delayed by 15 min
667.97MMarket Cap
1.82P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Rigel Pharmaceuticals Inc is 8.00, ranking 56 out of 155 in the Pharmaceuticals industry. The average price target is 42.00, with a high of 69.00 and a low of 24.00.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
55.200
Target Price
+41.28%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
54
Total
5
Median
7
Average
Company name
Ratings
Analysts
Rigel Pharmaceuticals Inc
RIGL
5
Apple Inc
AAPL
48
Ge Vernova Inc
GEV
37
Tapestry Inc
TPR
24
Verisk Analytics Inc
VRSK
20
Avantor Inc
AVTR
18
1
2
3
...
11
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Rigel Pharmaceuticals Inc's expected revenue for the next quarter?
Rigel Pharmaceuticals Inc's expected revenue is 69.46M.
What is Rigel Pharmaceuticals Inc's price target?
Analysts forecast that Rigel Pharmaceuticals Inc's price target is USD 42.00, with the highest forecast at USD 69.00 and the lowest forecast at USD 24.00.
How have Rigel Pharmaceuticals IncRIGL's recent earnings per share performed?
The market expectation was USD 0.47, while Rigel Pharmaceuticals IncRIGL's earnings per share (EPS) for the previous quarter was USD 14.72. EPS for the next quarter is expected at USD 0.62.
What is the analyst rating for Rigel Pharmaceuticals Inc?
Based on the ratings of Rigel Pharmaceuticals Inc's stock from 5 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.